Skip to main content
OpenTrials
Completed

NCT Number: NCT04572009

Validation of a Biomathematical Model to Help Identify the Parameters of Flexible Insulin Therapy

Type 1 diabetes is an autoimmune disease that requires daily treatment with insulin. The use of subcutaneous pumps for continuous insulin delivery has been an important advance for diabetic patients. The evolution of technologies through the miniaturization of insulin pumps and the advent of continuous glucose sensors has made it possible to understand the development of the artificial pancreas. Several teams are working on the development of an artificial pancreas with considerable progress in closed-loop insulin delivery, particularly during the night.

The Laboratory of Digital Sciences of Nantes has developed a new bio-mathematical model describing the glucose-insulin dynamics, closer to the physiological reality of patients with type 1 diabetes. This model allows firstly to identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios).

The objective of this study is to test the relevance of this bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU de Nantes

Nantes, 44093, France

About this study

This is an open randomized pilot clinical study, comparing the effectiveness of medical decision assisted by this bio-mathematical model ("augmented physician") versus unassisted medical decision, to define the parameters of flexible insulin therapy based on data from a continuous glucose measurement record for 7 days.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with type 1 diabetes for at least two years with an indication for sensor placement,
  • Patient patient with at least 6 months of external insulin pump therapy and using the Medtronic 640G pump with or without the Enlite® System.
  • Patient having at least 6 months experience of flexible insulin therapy,
  • Patient with HbA1c <10% (less than 4 months' duration of testing in a medical laboratory or equivalent),
  • Patient who has been wearing a Continuous Glucose Monitoring device for at least 3 months,
  • Adult patient,
  • Patient affiliated to a Social Security or equivalent,
  • Patient who has signed Informed Consent Form.

Exclusion criteria

  • Patient with type 2 diabetes or secondary diabetes
  • Patient with any serious medical condition that may affect participation in the study,
  • Patient benefiting from a legal protection measure,
  • Woman who is pregnant or likely to become pregnant during the course of the study, i.e., a lack of effective contraception in women of childbearing age,
  • Breastfeeding,
  • Psychological and/or physical condition that may affect the proper monitoring of study procedures,
  • Severe hypoglycemia leading to convulsions or loss of consciousness within the last 12 months,
  • Decreased hypoglycemic feelings (as judged by the clinician),
  • Impaired renal function (creatinine clearance calculated by CKD-EPI < 30mL/min),
  • Patient who has had a pancreas transplant or pancreatic islets,
  • Persons with severe uncorrected hearing and/or visual acuity problems,
  • Insulin resistance defined by daily insulin requirements > 1 U/kg/day in the week prior to inclusion,
  • Patient treated with oral corticosteroid therapy.

Treatment and study plan

Bio-mathematical model

Other

bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)

Without bio-mathematical model

Other

No bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)

Primary outcomes

  1. percentage of time in glycemic target

    Time frame: 4 weeks

    percentage of time in glycemic target (70-180 mg/dL) during the four weeks following medical consultation where the parameters of flexible insulin therapy are estimated by the physician, either conventionally or with the help of the bio-mathematical model, and parameterized in the insulin pump.

Secondary outcomes

  1. Coefficient of variation of glucose

    Time frame: 75 days

    Hypoglycemic readings < 0.7 g/L, Time below 0.7 g/L, Time above 1.8 g/L

  2. Frequency of severe hypoglycemia

    Time frame: 75 days

    Frequency of severe hypoglycemia (requiring the intervention of a third party)

  3. Robustness of the model

    Time frame: 75 days

    for each glycemic holter, identification of the model from the first 3 days of recording and comparison during the last 3 days of the predicted results with the observed glucose levels. And comparison, in the "delayed modelling" arm, of the doses estimated by the diabetologist and the doses estimated from the model.

  4. assessment of patient compliance

    Time frame: 75 days

    evaluation of the difference between the theoretical doses recommended following modelling and the actual doses given by the patient

  5. assessment of patient acceptance

    Time frame: 75 days

    Quality of life questionnaire SF36

  6. the average time of medical consultation in each group.

    Time frame: 75 days

    Duration of the consultation

  7. changes in heart rate over time

    Time frame: 75 days

  8. changes in activity over time

    Time frame: 75 days

Sponsors and collaborators

Lead sponsor

Nantes University Hospital

Other

Registry information

Official study title

Validation of a Biomathematical Model to Help Identify the Parameters of Flexible Insulin Therapy: Monocentric, Controlled, Randomized and Prospective Pilot Clinical Study in Patients With Type 1 Diabetes.

Acronym: ModIF

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Oct 1, 2020
Registry last updated
Oct 21, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.